BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
TRODELVY (sacituzumab govitecan) by Gilead Sciences. Approved for triple negative breast cancer, metastatic breast cancer, metastatic urothelial cancer. First approved in 2020.
TRODELVY (sacituzumab govitecan) is an antibody-drug conjugate (ADC) that combines an anti-TROP-2 monoclonal antibody with the chemotherapy payload SN-38. It is indicated for metastatic triple-negative breast cancer and urothelial carcinoma, delivering targeted cytotoxic therapy to TROP-2-expressing tumor cells.
$0.005BPart D
PeakProduct is at peak commercial maturity with modest Part D penetration; brand team likely stabilized in size with focus on market share defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on TRODELVY at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.